Operating Segments

9 Months Ended

Sep. 30, 2013

Operating Segments [Abstract]

Operating Segments

Note 8. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended September 30,
	2013			2012
Revenues, Principally from Grants
Vaccines/BioDefense	$	264,920		$	862,919
BioTherapeutics		47,571			68,708
Total	$	312,491		$	931,627
Loss from Operations
Vaccines/BioDefense	$	(419,929	)	$	19,190
BioTherapeutics		(1,080,436	)		(155,713	)
Corporate		(360,297	)		(623,693	)
Total	$	(1,860,662	)	$	(760,216	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	28,316		$	31,357
BioTherapeutics		29,233			32,180
Corporate		551			495
Total	$	58,100		$	64,032
Other Income /(Expense), Net
Corporate	$	(4,699,194	)	$	1,250
Stock-Based Compensation
Vaccines/BioDefense	$	39,493		$	29,103
BioTherapeutics		158,142			(49,275	)
Corporate		209,256			167,944
Total	$	406,891		$	147,772

	Nine Months Ended September 30,
	2013			2012
Revenues, Principally from Grants
Vaccines/BioDefense	$	1,683,265		$	2,170,761
BioTherapeutics		161,858			171,135
Total	$	1,845,123		$	2,341,896
Income (Loss) from Operations
Vaccines/BioDefense	$	(1,983,396	)	$	(111,319	)
BioTherapeutics		(2,068,703	)		(1,363,572	)
Corporate		(1,652,344	)		(1,707,992	)
Total	$	(5,704,443	)	$	(3,182,883	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	83,951		$	84,308
BioTherapeutics		86,303			86,913
Corporate		1,412			1,564
Total	$	171,666		$	172,785
Other Income /(Expense), Net
Corporate	$	(5,347,984	)	$	5,284
Stock-Based Compensation
Vaccines/BioDefense	$	61,742		$	33,363
BioTherapeutics		205,083			63,339
Corporate		304,346			286,072
Total	$	571,171		$	382,774

	As of September 30,  2013		As of December 31, 2012
Identifiable Assets
Vaccines/BioDefense	$	442,407	$	628,494
BioTherapeutics		411,847		566,111
Corporate		6,795,793		3,510,499
Total	$	7,650,047	$	4,705,104